<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04114747</url>
  </required_header>
  <id_info>
    <org_study_id>Kidney and dialysis</org_study_id>
    <nct_id>NCT04114747</nct_id>
  </id_info>
  <brief_title>Renal Physiology During Continuous Renal Replacement Therapy</brief_title>
  <official_title>Impact of Continuous Renal Replacement Therapy on Renal Oxygenation, Blood Flow and Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 50% of patients in the intensive care unit (ICU) develop acute kidney injury
      (AKI) and more than 10% need dialysis. There is no treatment for AKI, but care is aiming for
      optimization of circulation and blood flow to the kidneys and avoiding nephrotoxic agents.

      There is conflicting data concerning whether early or late dialysis is harmful for the
      kidneys. No one has examined the physiological changes in the kidney when starting dialysis
      and which blood pressure that leads to most optimal physiological conditions for the kidneys
      during dialysis. In this descriptive study of 20 ICU patients suffering from AKI we aim to
      investigate renal physiology when starting continuous renal replacement therapy (CRRT) and
      also at different target blood pressures using retrograde renal vein thermodilution
      technique. In parallel we will also investigate and validate this invasive method with
      contrast enhanced ultrasound of the kidneys.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>To describe renal physiology parameters when starting CRRT and compare renal physiology parameters when using high blood pressure target (MAP 80-90 mmHg) and low blood pressure target (MAP 60-70 mmHg).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal blood flow and CRRT</measure>
    <time_frame>6 hours</time_frame>
    <description>Changes in renal blood flow when CRRT is started? How will renal blood flow and oxygenation change at different blood pressure targets?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal blood flow and blood pressure</measure>
    <time_frame>6 hours</time_frame>
    <description>Renal blood flow changes at different mean arterial blood pressure targets during CRRT?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular filtration rate (GFR) and blood pressure</measure>
    <time_frame>6 hours</time_frame>
    <description>GFR changes at different mean arterial blood pressure targets during CRRT?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular filtration rate (GFR) and CRRT</measure>
    <time_frame>6 hours</time_frame>
    <description>Changes in GFR when CRRT is started?</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal oxygenation during CRRT</measure>
    <time_frame>6 hours</time_frame>
    <description>Renal oxygenation before CRRT and during CRRT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal oxygenation and blood pressure</measure>
    <time_frame>6 hours</time_frame>
    <description>Renal oxygenation changes at different mean arterial blood pressure targets during CRRT?</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contrast enhanced renal ultrasound (CEUS)</measure>
    <time_frame>2 hours</time_frame>
    <description>Validation of CEUS compared to retrograde renal vein thermodilution in measuring renal blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atrial natriuretic peptide (ANP)</measure>
    <time_frame>6 hours</time_frame>
    <description>Differences in serum atrial natriuretic peptide (ANP) during CRRT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>AKI</condition>
  <condition>Continuous Renal Replacement Therapy</condition>
  <condition>Dialysis</condition>
  <condition>Intensive Care</condition>
  <condition>Renal Blood Flow</condition>
  <condition>Renal Failure</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Starting at high blood pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm are randomized to have high target blood pressure at MAP 80-90 mmHg during the first recordings, thereafter they will receive low blood pressure target 60-70 mm Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Starting at low blood pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm are randomized to have low target blood pressure at MAP 60-70 mmHg during the first recordings, thereafter they will receive high blood pressure target 80-90 mm Hg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Starting at high or low blood pressure</intervention_name>
    <description>Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target</description>
    <arm_group_label>Starting at high blood pressure</arm_group_label>
    <arm_group_label>Starting at low blood pressure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        AKI, according to KDIGO, stage 2 or 3 but with preserved urine production. Treated in the
        ICU at Sahlgrenska University Hospital Written, signed informed consent Male and female
        subjects â‰¥18 years

        Exclusion Criteria:

        Emergency need for dialysis Allergy to contrast media (used for CEUS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Svennerholm, MD PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Kristina Svennerholm, MD PhD</last_name>
    <phone>+46313429336</phone>
    <email>kristina.svennerholm@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Rylander, MD PhD</last_name>
    <phone>+46313421000</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Svennerholm, MD PhD</last_name>
      <phone>+46313429336</phone>
      <email>kristina.svennerholm@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Oskar Juvakka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Kristina Svennerholm</investigator_full_name>
    <investigator_title>Principal investigator, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

